Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022

Description:
Next-generation antibody therapeutics refer to the improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Next-generation antibody-based therapeutics overcome the limitations of monoclonal antibodies and feature enhancements to existing properties of therapeutic antibodies. Various biotechnology and biopharmaceutical companies are actively involved in development of next-generation antibody therapeutics, especially for cancer, autoimmune, and inflammatory diseases. Factors such as growing R&D activities, increasing prevalence of chronic diseases, technological advancements in antibody therapeutics, and rising healthcare expenditure are driving growth of the global next-generation antibody therapeutics market. However, stringent regulatory requirements, long approval times for new drugs, and high costs of next-generation antibody therapeutics are some of the key restraints for growth of the market.

North America is the largest market for next-generation antibody therapeutics. The U.S. represents the largest market for next-generation antibody therapeutics in the region. This is due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing R&D activities in the country.

This report provides in-depth analysis and estimation of the global next-generation antibody therapeutics market for the period 2015–2022, considering 2014 as the base year for calculations. In addition, data pertaining to current market dynamics, including market drivers, restraints, and strategic developments has been provided in the report. The next-generation antibody therapeutics market is categorized on the basis of technology, therapeutic application, and geography. Based on technology, the next-generation antibody therapeutics market is segmented into antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. In terms of therapeutic application, the market is segmented into oncology and autoimmune/inflammatory diseases. In the geographical analysis, the report identifies and analyzes market size and forecast for North America, Europe, Asia, and Rest of the World (RoW).

Some of the major players in the market are F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.

Contents:
Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology
1.3 Assumptions
Chapter 2 Market Synopsis
Chapter 3 Porter’s Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry
Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

4.2.1 Growing R&D activities

4.2.2 Increasing prevalence of chronic diseases

4.2.3 Technological advancements in antibody therapeutics

4.2.4 Increasing healthcare expenditure

4.3 Impact Analysis of Market Drivers

4.4 Restraints

4.4.1 Stringent regulatory requirements and long approval times for new drugs

4.4.2 High costs of next-generation antibody therapeutics

4.5 Impact Analysis of Market Restraints

4.6 Market Trends

4.6.1 Increasing usage of antibody-drug conjugates (ADC) technology is gaining popularity in next-generation antibody therapeutics market

4.6.2 Rising number of collaborations for development of next-generation antibody therapeutics

Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs

Chapter 6 Global Market Size and Forecast

6.1 On the Basis of Geography

6.2 On the Basis of Therapeutic Area

6.3 On the Basis of Technology

Chapter 7 Market Size and Forecast by Therapeutic Area

7.1 Oncology

7.2 Autoimmune/Inflammatory

Chapter 8 Market Size and Forecast by Technology

8.1 Antibody-drug conjugates (ADCs)

8.2 Bispecific antibodies

8.3 Fc engineered antibodies

8.4 Antibody fragments and antibody-like proteins

8.5 Biosimilar antibody products

Chapter 9 Market Size and Forecast by Geography

9.1 North America
9.2 Europe
9.3 Asia
9.4 Rest of the World

Chapter 10 Competitive Scenario
10.1 Competitive Benchmarking
10.2 Company Share Analysis

Chapter 11 Company Profiles
11.1 F. Hoffmann-La Roche Ltd
   11.1.1 Company Overview
   11.1.2 Products and services
   11.1.3 Financial performance
   11.1.4 Key Developments

11.2 Kyowa Hakko Kirin Co., Ltd.
   11.2.1 Company Overview
   11.2.2 Products and Services
   11.2.3 Financial performance
   11.2.4 Key Developments

11.3 Seattle Genetics, Inc.
   11.3.1 Company Overview
   11.3.2 Products and Services
   11.3.3 Financial performance
   11.3.4 Key Developments

11.4 ImmunoGen, Inc.
   11.4.1 Company Overview
   11.4.2 Products and Services
   11.4.3 Financial performance
   11.4.4 Key Developments

11.5 Bristol-Myers Squibb Company
   11.5.1 Company Overview
   11.5.2 Products and Services
   11.5.3 Financial performance
   11.5.4 Key Developments
11.6 Pfizer, Inc.
   11.6.1 Company Overview
   11.6.2 Products and Services
   11.6.3 Financial performance
   11.6.4 Key Developments

11.7 Amgen, Inc.
   11.7.1 Company Overview
   11.7.2 Products and Services
   11.7.3 Financial performance
   11.7.4 Key Developments

11.8 Biogen
   11.8.1 Company Overview
   11.8.2 Products and Services
   11.8.3 Financial performance
   11.8.4 Key Developments

11.9 Bayer AG
   11.9.1 Company Overview
   11.9.2 Products and Services
   11.9.3 Financial performance
   11.9.4 Key Developments

11.10 Xencor, Inc.
   11.10.1 Company Overview
   11.10.2 Products and Services
   11.10.3 Financial performance
   11.10.4 Key Developments

11.11 Takeda Pharmaceuticals Company Limited
   11.11.1 Company Overview
   11.11.2 Products and services
   11.11.3 Financial performance
   11.11.4 Key Developments

11.12 AstraZeneca
11.12 Company Overview
11.12.2 Products and Services
11.12.3 Financial performance
11.12.4 Key Developments
11.13 Dyax Corp.
11.13.1 Company Overview
11.13.2 Products and Services
11.13.3 Financial performance
11.13.4 Key Developments

List of Tables

TABLE 1 Market snapshot: Next-generation antibody therapeutics market, 2015 and 2022
TABLE 1 Drivers for next-generation antibody therapeutics market: Impact analysis
TABLE 2 Estimated average timelines for clinical trial approval in various countries
TABLE 3 Restraints for next-generation antibody therapeutics market: Impact analysis
TABLE 4 Major collaborations in next-generation antibody therapeutics market (2012- April 2015)
TABLE 6 Global next-generation antibody therapeutics market size, by region, 2010 – 2013 (US$ Mn)
TABLE 7 Global next-generation antibody therapeutics market size, by region, 2014 – 2020 (US$ Mn)
TABLE 8 Global next-generation antibody therapeutics market size, by therapeutic area, 2010 – 2013 (US$ Mn)
TABLE 9 Global next-generation antibody therapeutics market size, by application, 2014 – 2020 (US$ Mn)
TABLE 10 Global next-generation antibody therapeutics market size, by technology, 2010 – 2013 (US$ Mn)
TABLE 11 Global next-generation antibody therapeutics market size, by technology, 2014 – 2020 (US$ Mn)
TABLE 12 Global oncology next-generation Ab therapeutics market size, by region, 2010 – 2013 (US$ Mn)
TABLE 13 Global oncology next-generation Ab therapeutics market size, by region, 2014 – 2020 (US$ Mn)
TABLE 14 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2010 – 2013 (US$ Mn)
TABLE 15 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2014 – 2020 (US$ Mn)
TABLE 16 Global ADCs market size, by region, 2010 – 2013 (US$ Mn)
TABLE 17 Global ADCs market size, by region, 2014 – 2020 (US$ Mn)
TABLE 18 Global BsAbs market size, by region, 2010 – 2013 (US$ Mn)
TABLE 19 Global BsAbs market size, by region, 2014 – 2020 (US$ Mn)
TABLE 20 Global Fc engineered antibodies market size, by region, 2010 – 2013 (US$ Mn)
TABLE 21 Global Fc engineered antibodies market size, by region, 2014 – 2020 (US$ Mn)
TABLE 22 Global antibody fragments and antibody-like proteins market size, by region, 2010 – 2013 (US$ Mn)
TABLE 23 Global antibody fragments and antibody-like proteins market size, by region, 2014 – 2020 (US$ Mn)
TABLE 24 Global biosimilar antibody products market size, by region, 2010 – 2013 (US$ Mn)
TABLE 25 Global biosimilar antibody products market size, by region, 2014 – 2020 (US$ Mn)
TABLE 26 North America next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn)
TABLE 27 North America next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn)
TABLE 28 Europe next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn)
TABLE 29 Europe next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn)
TABLE 30 Asia next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn)
TABLE 31 Asia next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn)
TABLE 32 Major product categories of Roche
TABLE 33 Major product segments of Kyowa Hakko Kirin Co., Ltd.
TABLE 34 Major product categories of Seattle Genetics, Inc.
TABLE 35 Product category of ImmunoGen, Inc.
TABLE 36 Major product segments of Bristol-Myers Squibb Company
TABLE 37 Major product segments of Pfizer, Inc.
TABLE 38 Major product categories of Amgen
TABLE 39 Major categories of therapies of Biogen
TABLE 40 Major product categories of Bayer AG
TABLE 41 Product category of Xencor
TABLE 42 Major product categories of Takeda
TABLE 43 Major product categories of AstraZeneca
TABLE 44 Product category of Dyax Corp.

List of Figures
FIG. 1 Next-generation antibody therapeutics market: Porter’s five force analysis
FIG. 2 Health expenditure as total percentage of GDP, 2002 and 2012
FIG. 3 Global next-generation antibody therapeutics market share, by region, by value, 2013
FIG. 4 Global next-generation antibody therapeutics market share, by therapeutic area, by value, 2013
FIG. 5 Global next-generation antibody therapeutics market share, by technology, by value, 2013
FIG. 6 Global oncology next-generation Ab therapeutics market share, by region, by value, 2013
FIG. 7 Global autoimmune/inflammatory next-generation Ab therapeutics market share, by region, by value, 2013
FIG. 8 Global ADCs market share, by region, by value, 2013
FIG. 9 Global BsAbs market share, by region, by value, 2013
FIG. 10 Global Fc engineered antibodies market share, by region, by value, 2013
FIG. 11 Global antibody fragments and antibody-like proteins market share, by region, by value, 2013
FIG. 12 Global biosimilar antibody products market share, by region, by value, 2013
FIG. 13 North America next-generation antibody therapeutics market share, by country, by value, 2013
FIG. 16 Europe next-generation antibody therapeutics market share, by country, by value, 2013
FIG. 17 Asia next-generation antibody therapeutics market share, by country, by value, 2013
FIG. 18 Competitive benchmarking of next-generation antibody therapeutics
FIG. 19 Global next-generation antibody therapeutics market, by company 2014 (% share)
FIG. 20 Sales and net income of Roche, 2012 – 2014 (US$ Mn)
FIG. 21 Net sales and net income of Kyowa Hakko Kirin Co., Ltd., 2012 – 2014 (US$ Mn)
FIG. 22 Total revenue and net loss of Seattle Genetics, Inc., 2012 – 2014 (US$ Mn)
FIG. 23 Total revenue and net loss of ImmunoGen, Inc., 2012 – 2014 (US$ Mn)
FIG. 24 Total revenue and net earnings of Bristol-Myers Squibb Company, 2012 – 2014 (US$ Mn)
FIG. 25 Revenue and net income of Pfizer, Inc., 2012 – 2014 (US$ Mn)
FIG. 26 Revenue and net income of Amgen, 2012 – 2014 (US$ Mn)
FIG. 27 Total revenue and net income of Biogen, 2012 – 2014 (US$ Mn)
FIG. 28 Net sales and net income of Bayer AG, 2012 – 2014 (US$ Mn)
FIG. 29 Revenues and net loss of Xencor, 2012 – 2014 (US$ Mn)
FIG. 30 Revenue and net profit of Takeda, 2012 – 2014 (US$ Mn)
FIG. 31 Revenue and profit of AstraZeneca, 2012 – 2014 (US$ Mn)
FIG. 32 Total revenue and net loss of Dyax Corp., 2012 – 2014 (US$ Mn)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3422607/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022
Web Address: http://www.researchandmarkets.com/reports/3422607/
Office Code: SCBR8FAY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4900</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 7600</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10600</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
First Name:  
Email Address: *  
Job Title:  
Organisation:  
Address:  
City:  
Postal / Zip Code:  
Country:  
Phone Number:  
Fax Number:  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World